PMID: 16614730Apr 15, 2006Paper

Hypoxic pulmonary hypertension (HPH) and iptakalim, a novel ATP-sensitive potassium channel opener targeting smaller arteries in hypertension

Cardiovascular Drug Reviews
Hai WangYing-Li Zhang

Abstract

Hypoxic pulmonary hypertension (HPH) is a serious and potentially devastating chronic disorder of the pulmonary circulation. Attempts to use drugs in the therapy of hypoxic pulmonary hypertension indicated the importance of prevention or reduction of vasoconstriction as well as of the reversal of remodeling within the cardiovascular system. Iptakalim (2,3-dimethyl-N-(1-methylethyl)-2-butylamine), a novel ATP-sensitive potassium channel opener, has the desired effects on hypoxic pulmonary arteries. Iptakalim decreases the elevated mean pressure in pulmonary arteries, and attenuates remodeling in the right ventricle, pulmonary arteries and airways. Moreover, iptakalim has selective antihypertensive effects: it significantly lowers arterial pressure in hypertensive animals, but has little if any effect in normotensive animals. In HPH iptakalim has selective effects on smaller arteries. Long-term iptakalim therapy decreases expression of sulfonylurea receptor 2 and of mRNA of inwardly rectifying potassium channel in smaller arteries of spontaneously hypertensive rats. Iptakalim inhibits the effects of endothelin-1, reduces the intracellular calcium concentration and inhibits the cell cycle in smooth muscle cells of pulmonary arteri...Continue Reading

References

Jan 1, 1991·Toxicologic Pathology·M Rabinovitch
Mar 15, 1991·Annals of Internal Medicine·D J StewartD Langleben
Nov 1, 1990·American Journal of Respiratory Cell and Molecular Biology·T R MurrayE J Macarak
Mar 1, 1988·Chest·B M TwarogG L Campbell
Jan 1, 1986·British Journal of Diseases of the Chest·J HoganP Harris
Jun 22, 1984·The American Journal of Medicine·M PackerW H Lee
Sep 1, 1995·The American Journal of Medicine·P HervéL Drouet
Apr 1, 1995·The American Journal of Physiology·M T Nelson, J M Quayle
Jan 1, 1994·Journal of Neural Transmission. General Section·K P LeschP Riederer
Feb 1, 1994·Trends in Pharmacological Sciences·R M Wadsworth
May 1, 1994·American Journal of Respiratory and Critical Care Medicine·C A TozziD J Riley
May 1, 1994·The Journal of Clinical Investigation·K HishikawaT Saruta
Jul 1, 1993·Chest·L J Rubin
Jan 1, 1993·Journal of Applied Physiology·R D Russ, B R Walker
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
May 1, 1996·British Journal of Pharmacology·H L Zhang, T B Bolton
Nov 1, 1996·Journal of Applied Physiology·W HuangG Bledsoe
Jan 9, 1997·The New England Journal of Medicine·L J Rubin
Jul 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·M G FridK R Stenmark
Apr 29, 1998·Annual Review of Physiology·A P BabenkoJ Bryan
Sep 5, 1998·Lancet·S P Gaine, L J Rubin
Feb 13, 1999·The New England Journal of Medicine·W J Louis
May 14, 1999·General Pharmacology·K M McCullochA M Gurney
Aug 25, 1999·Proceedings of the Society for Experimental Biology and Medicine·M Kirchengast, K Münter
Oct 16, 1999·General Pharmacology·J P DumasM Dumas
Dec 22, 1999·Trends in Pharmacological Sciences·M R MacLean
Sep 23, 2000·American Journal of Physiology. Lung Cellular and Molecular Physiology·D D IvyS H Abman

❮ Previous
Next ❯

Citations

Dec 21, 2018·Antioxidants & Redox Signaling·Laura Weise-CrossNikki L Jernigan
Feb 9, 2012·The Journal of Pharmacy and Pharmacology·Yun CaiHai Wang
Oct 4, 2007·Annals of the New York Academy of Sciences·M Cerinic MatucciAlberto Pignone
May 15, 2012·International Journal of Molecular Medicine·Kai SunHong Wang
Oct 11, 2020·International Journal of Molecular Sciences·Pawan FarisFrancesco Moccia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.